Published Date: Feb 08 2023
Pharmaceutical intermediate is an important part of fine chemical industry, and its development level is the symbol of a country's chemical modernization level. Let's take a look at the status quo and development trend of pharmaceutical intermediates abroad.
1. Pharmaceutical intermediates are an important part of fine chemical industry
Its development level is the symbol of a country's chemical modernization level. For many years, the pharmaceutical intermediate industry has been the focus of the world's key investment and fierce competition. In the past two decades, the pharmaceutical industry in the world has made unprecedented progress. By the end of the 1990s, the scale of the world drug market has reached about 256 billion US dollars, and the sales of pesticide is about 23 billion US dollars. In terms of medicine, in the last decade, although biotechnology and genetic drugs as a newcomer achieve the continuous development, the important patent drugs are also being accepted. The future development trend of the world pharmaceutical industry is: high technology, high demand, high speed, high concentration.
2. The main characteristics of pharmaceutical intermediates are the following five aspects
(1) New drugs emerge in an endless stream and their varieties are updated at a faster pace. For example, quinolone acid antimicrobials. More than 20,000 compounds have been chemically synthesized and screened in the past 30 years. From 1962 to 1969, naphthobutyric acid, quinic acid and pyrrolitic acid were developed successfully. They were replaced by flumequine and piperate between 1970 and 1977. Since 1978, fluoroquinolone acids have appeared and become the third generation of quinolone antimicrobials, such as ciprofloxacin, Lomefloxacin and ofloxacin. Their antibacterial spectrum is wide, the activity is stronger, and the efficacy can be compared with the third or fourth generation of cephalosporins.
(2) As the difficulty of new drug creation becomes greater, the administrative departments have higher and higher requirements for the efficacy and safety of drugs, which makes the investment in research and development surge. At the same time, new drug research and development is a long-term and continuous process; And it's extremely risky. It costs a lot of money to adapt to the competition in the high-tech sector. In developed countries, R&D expenses as a percentage of turnover exceed turnover margins.
(3) As a high-tech industry, the pharmaceutical intermediates industry needs high knowledge content. Pharmaceutical enterprises in various countries are constantly improving the strength of their research teams. For example, scientific researchers in American pharmaceutical enterprises account for 15% of the employees, among which 26.7% have obtained doctor's and master's degrees.
(4) The increase of giant enterprises. Pharmaceutical companies in developed countries expand their economic strength and research capacity through mergers and acquisitions to occupy the market and strive to enter the best scale. For drugs that have the potential to become bulk products, such as naproxen piperazinic acid, ranitidine, etc., before the patent protection period expires, the competition is about finding partners, developing new technological routes and new production technologies, developing production, reducing costs and expanding sales, so as to better participate in international competition.
Links to the article source: http://olda.b2star.com/news-3551